Company Description

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States.

Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.

The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library.

Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.